ホーム › 肝臓がん（肝細胞がん） › ペンシルベニア
ペンシルベニアにおける肝臓がん（肝細胞がん）の臨床試験
ペンシルベニア内の拠点で、肝臓がん（肝細胞がん）に関する27件の研究が参加者を募集しています。
ペンシルベニア内の都市
公式研究テキスト（英語）
A Phase 1 Study of the Safety and Tolerability of CTX-10726
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07419841Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #104, Hershey
- Exelixis Clinical Site #98, Philadelphia
- Exelixis Clinical Site #32, Pittsburgh
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483National Liver Cancer Screening Trial
- University of Pennsylvania, Philadelphia
被験者募集中第4相
18歳〜85歳 · 全性別 · 2026/09/25更新 · NCT06084234A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT06427941Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- Lehigh Valley Hospital, Allentown
被験者募集中観察研究
22歳以上 · 全性別 · 2026/09/11更新 · NCT06486454Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06811116Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Philadelphia
- Research Site, Pittsburgh
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06921785Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119FOG-001 in Locally Advanced or Metastatic Solid Tumors
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05919264Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- Christiana Care Health System-Concord Health Center, Chadds Ford
- Geisinger Medical Center, Danville
- Geisinger Cancer Center Dickson City, Dickson City
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT07166406Molecular Basis of Pediatric Liver Cancer
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
被験者募集中観察研究
0歳〜99歳 · 全性別 · 2026/08/10更新 · NCT03959800Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
- Allegheny General Hospital, Pittsburgh
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05168163A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Thomas Jefferson University, Philadelphia
被験者募集中第2相
8歳以上 · 全性別 · 2026/07/27更新 · NCT05503797Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/23更新 · NCT04114136A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Pittsburgh
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/17更新 · NCT06600321Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
被験者募集中
18歳〜75歳 · 全性別 · 2026/06/17更新 · NCT05486572Y-90 Treatment Response Using Transarterial Radioembolization
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/10更新 · NCT07145801Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
- University of Pennsylvania, Philadelphia
被験者募集中第1/2相
20歳〜99歳 · 全性別 · 2026/04/20更新 · NCT02174549Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/16更新 · NCT07223424Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/16更新 · NCT05842174Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/02更新 · NCT05733598SBRT With Atezo/Bev for HCC
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
被験者募集中第1相
18歳〜99歳 · 全性別 · 2026/02/20更新 · NCT05488522Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients
- Thomas Jefferson Hospital, Philadelphia
被験者募集中観察研究
18歳以上 · 全性別 · 2026/01/26更新 · NCT05705219Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- Penn State Hershey Medical Center, Hershey
- Albert Einstein Healthcare Network, Philadelphia
被験者募集中第4相
18歳〜64歳 · 全性別 · 2026/01/22更新 · NCT04373564Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/01/21更新 · NCT03539822Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第2相
18歳以上 · 全性別 · 2025/11/06更新 · NCT06698250SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Philadelphia
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。